BioAge Labs, Inc. - Common Stock (BIOA)

BioAge Labs halts STRIDES Phase 2 trial of azelaprag after liver enzyme elevations, plans further analysis with updates expected in Q1 2025.

Self-driving startup Pony.ai of China filed for an IPO in the U.S. this week. Meanwhile, four companies -- Springview Holdings, Oriental Rise Holdings, PTL Limited, and Samfine Creation Holdings Group -- saw their stocks open for trading.

The key word here is "could."

The future of the weight loss market might not revolve around GLP-1 drugs.

BioAge Labs is the latest pharmaceutical company looking to make waves in the weight loss realm.

One of these businesses is a risky play, but the other is very likely to succeed.

There's a chance that its lead candidate could become one of the top drugs ever.

BioAge has its eyes on a handful of truly gargantuan markets.

Shares of BioAge Labs opened for trading this week, with the company planning to use the proceeds of its initial public offering to take its lead obesity drug further into clinical trials.

The company is working on a drug that mimics apelin, which is released following exercise.